Bristol Myers Squibb (BMY) Gross Margin (2009 - 2026)
Bristol Myers Squibb (BMY) reported Gross Margin of 70.22% for Q1 2026, down 270.0% year-over-year from 41.31% in Q1 2025, and up 4.45% on a QoQ basis from 67.23% in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Gross Margin data on file, last reported at 70.22% in Q1 2026.
- Quarterly Gross Margin fell 270.0% year-over-year to 70.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70.45% (down 1.0% YoY) and the FY2025 annual result came in at 71.08%, changed 0.0% from the prior year.
- Gross Margin improved to 70.22% in Q1 2026 per BMY's latest filing, from 67.23% in the prior quarter.
- Across five years, Gross Margin topped out at 79.02% in Q3 2022 and bottomed at 61.01% in Q4 2024.
- The 5-year median for Gross Margin is 75.13% (2024), against an average of 73.92%.
- The widest annual swing landed in 2024, when Gross Margin slumped 1507 bps; it then soared 622 bps in 2025.
- Tracing BMY's Gross Margin over 5 years: stood at 77.27% in 2022, then retreated by 2 bps to 76.08% in 2023, then declined by 20 bps to 61.01% in 2024, then rose by 10 bps to 67.23% in 2025, then advanced by 4 bps to 70.22% in 2026.
- Per Business Quant, the three latest BMY Gross Margin figures stand at 70.22% (Q1 2026), 67.23% (Q4 2025), and 71.89% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 70.22% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.22% |
| Dec 31, 2025 | 67.23% |
| Sep 30, 2025 | 71.89% |
| Jun 30, 2025 | 72.52% |
| Mar 31, 2025 | 72.92% |
| Dec 31, 2024 | 61.01% |
| Sep 30, 2024 | 75.13% |
| Jun 30, 2024 | 73.22% |
| Mar 31, 2024 | 75.29% |
| Dec 31, 2023 | 76.08% |
| Sep 30, 2023 | 77.15% |
| Jun 30, 2023 | 74.38% |
| Mar 31, 2023 | 77.37% |
| Dec 31, 2022 | 77.27% |
| Sep 30, 2022 | 79.02% |
| Jun 30, 2022 | 77.12% |
| Mar 31, 2022 | 78.79% |
| Dec 31, 2021 | 80.34% |
| Sep 30, 2021 | 80.29% |
| Jun 30, 2021 | 79.05% |
| Mar 31, 2021 | 74.34% |
| Dec 31, 2020 | 73.71% |
| Sep 30, 2020 | 76.26% |
| Jun 30, 2020 | 73.35% |
| Mar 31, 2020 | 66.03% |
| Dec 31, 2019 | 68.63% |
| Sep 30, 2019 | 70.20% |
| Jun 30, 2019 | 68.56% |
| Mar 31, 2019 | 69.19% |
| Dec 31, 2018 | 73.05% |
| Sep 30, 2018 | 71.04% |
| Jun 30, 2018 | 71.51% |
| Mar 31, 2018 | 69.50% |
| Dec 31, 2017 | 70.62% |
| Sep 30, 2017 | 69.95% |
| Jun 30, 2017 | 69.50% |
| Mar 31, 2017 | 74.34% |
| Dec 31, 2016 | 73.18% |
| Sep 30, 2016 | 73.49% |
| Jun 30, 2016 | 75.24% |
| Mar 31, 2016 | 76.04% |
| Dec 31, 2015 | 77.79% |
| Sep 30, 2015 | 73.04% |
| Jun 30, 2015 | 75.67% |
| Mar 31, 2015 | 79.04% |
| Dec 31, 2014 | 77.31% |
| Sep 30, 2014 | 74.32% |
| Jun 30, 2014 | 74.52% |
| Mar 31, 2014 | 74.60% |
| Dec 31, 2013 | 71.34% |
| Sep 30, 2013 | 71.09% |
| Jun 30, 2013 | 72.63% |
| Mar 31, 2013 | 72.25% |
| Dec 31, 2012 | 74.35% |
| Sep 30, 2012 | 73.58% |
| Jun 30, 2012 | 71.98% |
| Mar 31, 2012 | 75.19% |
| Dec 31, 2011 | 74.94% |
| Sep 30, 2011 | 73.68% |
| Jun 30, 2011 | 72.75% |
| Mar 31, 2011 | 73.20% |
| Dec 31, 2010 | 72.33% |
| Sep 30, 2010 | 73.32% |
| Jun 30, 2010 | 73.22% |
| Mar 31, 2010 | 72.83% |
| Dec 31, 2009 | 71.53% |
| Sep 30, 2009 | 72.49% |
| Jun 30, 2009 | 73.74% |
| Mar 31, 2009 | 73.04% |